MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
Byoung Chul Cho(Yonsei University), Alexander I. Spira(Virginia Cancer Specialists), Benjamin Besse(Institut Gustave Roussy), Hidetoshi Hayashi(Kindai University), Tao Sun(Wuhan University), Enriqueta Felip(Institut Català d'Ornitologia), Michael Thomas, Seema Sethi(Janssen (United States)), Shun Lü(Shanghai Jiao Tong University), S. Martin Shreeve(Janssen (United States)), Melissa Martínez(Carilion Clinic)
Cited by 93
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k